Regeneron, GSK see massive spike in Covid-19 mAb demand as US debates buying more
The Delta variant is busy driving up new Covid-19 cases nationwide, accelerating demand for monoclonal antibody treatments from Regeneron and GlaxoSmithKline, which can reduce hospitalizations and deaths if used appropriately.
Regeneron has seen a dramatic increase in demand for its mAb cocktail of casirivimab plus imdevimab in just the past month. The company has led the mAb field since nabbing an early EUA for the drug, which can now be administered subcutaneously.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.